Company intelligence / Profile preview

Little Bay

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Little Bay is a pre-clinical stage biotechnology company focused on developing transformative therapies for genetic diseases, with an initial emphasis on cystic fibrosis. The company leverages a proprietary platform to identify and develop small molecules that target RNA to restore protein function. By focusing on specific genetic mutations that are underserved by current treatments, Little Bay aims to provide new options for patients with limited therapeutic alternatives. The company was founded by experts in RNA biology and medicinal chemistry to bridge the gap in treating complex genetic disorders.

Therapeutic areas: Pulmonology
Modalities: Small moleculeGene therapy
Industry: Biotech

Beyond the preview

Go deeper on Little Bay.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Little Bay.

Explore the full profile